RCEL at a glance
AVITA Medical, Inc. (RCEL, SEC CIK 1762303) filed its latest 20-F annual report on October 31, 2019 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AVITA Medical, Inc. (RCEL) reported revenue of $71.6 million (up 11.5% from FY2024) and a net loss of $48.6 million. Diluted EPS was -$1.74.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding AVITA Medical, Inc. (RCEL) shares worth $48.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by O'Toole David D on June 12, 2026 of 2,000 shares at $3.97 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $71.6M
- +11.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $48.2M · +5 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material risk-factor changes from the 2025 Annual Report
- Carried-forward business, liquidity, operational, regulatory, and market risks remain applicable
- Potential adverse effects on financial condition, liquidity, results of operations, and capital position
- Actual results may differ materially from historical results and forward-looking statements
AI summary of the RCEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Perceptive received 119,375 shares after cashless exercise of a warrant covering 150,000 shares
- Company withheld 30,625 shares for the Perceptive Warrant exercise price, limiting net dilution
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for the quarter ended September 30, 2026
- Financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $26.1M, up 53% year over year and 20% sequentially, led by RECELL and growing Cohealyx adoption
- Gross margin 84.0%, up from 81.3%, while operating expenses reached $24.6M, limiting operating leverage
Item 7.01: Regulation FD Disclosure
- Perceptive exercised its warrant for up to 500,000 shares through a cashless exercise
- Company withheld 112,284 shares for the exercise price, limiting net issuance
AI summaries of RCEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RCEL
Don't miss the next RCEL filing
- Alerts as it files. A push when RCEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RCEL, by share count.
- Ask anything. An AI agent that reads every RCEL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| O'Toole David D | A | Jun 12, 2026 | 2,000 | $3.97 |
| O'Toole David D | Buy | Jun 12, 2026 | 2,000 | $3.97 |
| Woody Joseph Fralin | Buy | Jun 9, 2026 | 5,000 | $4.20 |
| Woody Joseph Fralin | Buy | Jun 9, 2026 | 5,000 | $4.18 |
| Woody Joseph Fralin | Buy | Jun 9, 2026 | 5,200 | $4.00 |
| Woody Joseph Fralin | Buy | Jun 3, 2026 | 5,000 | $4.10 |
| Woody Joseph Fralin | Buy | Jun 3, 2026 | 5,000 | $4.09 |
| Woody Joseph Fralin | Buy | Jun 2, 2026 | 5,000 | $4.21 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $50.1M | $64.3M | $71.6M |
| Gross Profit | - | $55.2M | $58.8M |
| Operating Income | - | -$56.6M | -$42.5M |
| Net Income | - | -$61.8M | -$48.6M |
| Gross Margin | - | 85.8% | 82.1% |
| Op. Margin | - | -88.1% | -59.4% |
| Net Margin | - | -96.3% | -67.8% |
| Balance Sheet | |||
| Total Assets | - | $79.7M | $56.4M |
| Equity | - | $4.5M | -$16.6M |
| ROE | - | -1374.6% | 291.8% |
| Per Share | |||
| EPS | - | $-2.39 | $-1.74 |
| Cash Flow | |||
| Operating CF | - | -$48.9M | -$31.2M |
| CapEx | $1.4M | $9.2M | $1.0M |
Source: XBRL data in AVITA Medical, Inc. (RCEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RCEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $48.2M |
| Q2 2026 | 15 | $11.8M |
| Q1 2026 | 17 | $13.7M |
| Q4 2025 | 17 | $12.7M |
| Q3 2025 | 17 | $19.2M |
| Q2 2025 | 21 | $27.7M |
| Q1 2025 | 18 | $23.7M |
| Q4 2024 | 13 | $31.9M |
- Millennium Management+355.2K (+2302%)
- Citadel Advisors LLC+206.4K (+972%)
- Goldman Sachs Group+189.9K (+247%)
- Bank of America Corp+56.7K (+110%)
- State Street Corp+23.1K (+18%)
- AQR Capital Management−279.9K (-87%)
- Morgan Stanley−159.8K (-80%)
- BlackRock−5.4K (-1%)
- PNC Financial Services−356 (-43%)
- Wells Fargo & Co−180 (-8%)
- Two Sigma Investments+503.9K
- D.E. Shaw & Co+232.0K
- Prudential Financial+90.2K
- Raymond James Financial+40.8K
- Renaissance Technologies LLC+19.1K
- FMR LLC (Fidelity)−32.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 138 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RCEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 20-F, 6-K
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 19, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
RCEL SEC filings: frequently asked questions
Which institutions hold RCEL stock?
As of September 30, 2026, the largest AVITA Medical, Inc. (RCEL) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($15.7 million), BlackRock ($6.6 million), Two Sigma Investments ($5.9 million), Millennium Management ($4.3 million), Goldman Sachs Group ($3.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RCEL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AVITA Medical, Inc. (RCEL) reported revenue of $71.6 million (up 11.5% from FY2024) and a net loss of $48.6 million. Diluted EPS was -$1.74. The figures come from the XBRL data in the 10-K.
What did RCEL report in its latest 8-K?
AVITA Medical, Inc. (RCEL) filed an 8-K on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure). Perceptive received 119,375 shares after cashless exercise of a warrant covering 150,000 shares.
What are the latest RCEL SEC filings?
AVITA Medical, Inc. (RCEL) filed its latest 20-F annual report on October 31, 2019 and a Form 4 insider filing on August 24, 2026.
What is RCEL's SEC CIK number?
AVITA Medical, Inc. (RCEL)'s SEC Central Index Key (CIK) is 1762303. EDGAR lists every RCEL filing under that number.
Ask anything about RCEL
The research agent reads RCEL's filings, financials, insider trades and 13F holders, then answers with sources.